Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell Carcinoma, Phase 2, Interventional Study

NCT04714697 is registered in ClinicalTrials.gov with Asan Medical Center as lead sponsor.

NCT NCT04714697
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04714697 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell Carcinoma, Phase 2, Interventional Study
Lead sponsor
Asan Medical Center
Phase
Phase 2
Overall status
Unknown status
Start date
March 1, 2021
Completion date
February 28, 2025
Enrollment
201 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell cancer